Eve, Heather E <br/><br/>
The Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide +/- rituximab: results of a randomized phase II trial.  [electronic resource] 

 -  Leukemia & lymphoma  Oct 2009 
 - 1709-11 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Comparative Study; Letter; Randomized Controlled Trial; Validation Study 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.1080/10428190903186494  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Lymphoma, Mantle-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Prognosis<br/>Rituximab<br/>Severity of Illness Index<br/>Survival<br/>Treatment Outcome<br/>Vidarabine--administration & dosage